PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2)
Silvana Novelli,
Ashish Risal,
Manjusha Namuduri,
Jingxian Cai,
Melanie Ufkin,
Min Zhu,
Sushmita Mukherjee,
Jurriaan Brouwer-Visser,
Aafia Chaudhry,
Hesham Mohamed,
Srikanth Ambati,
Elżbieta Iskierka-Jażdżewska
Affiliations
Silvana Novelli
1 Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Ashish Risal
2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States
Manjusha Namuduri
2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States
Jingxian Cai
2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States
Melanie Ufkin
2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States
Min Zhu
2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States
Sushmita Mukherjee
2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States
Jurriaan Brouwer-Visser
2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States
Aafia Chaudhry
2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States
Hesham Mohamed
2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States
Srikanth Ambati
2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States
Elżbieta Iskierka-Jażdżewska
3 Copernicus Memorial Hospital, Department of General Hematology, Medical University of Łódź, Łódź, Poland
